Alnylam Pharmaceuticals | ALNY - Ordinary Share Capital


Alnylam Pharmaceuticals reported $133.88M in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amgen USD 541M 1000K Jun/2026
Arrowhead Research USD 141.14M 564K Jun/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Moderna USD 391M 2M Sep/2025
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.91B 60K Mar/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Sanofi EUR 1.2B 16.88M Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Takeda JPY 1.58B 460K Jun/2026
Tectonic Therapeutic USD 18.83M 92.19K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026
Xencor USD 74.33M 265K Jun/2026